Table 2. Treatment characteristics.
| Characteristic | Sequential | Unilobar | Whole liver | All | OS (P value) | Overall PFS | Intrahepatic PFS | Distant PFS |
|---|---|---|---|---|---|---|---|---|
| n | 64 | 28 | 24 | 116 | – | – | – | – |
| Percent (%) | 55.2 | 24.1 | 20.7 | 100 | – | – | – | – |
| Prescribed activity treatment 1 (mCi) | 33.9 | 35.5 | 46.6 | 36.90 | 0.615 | 0.916 | 0.946 | 0.850 |
| Delivered activity treatment 1 (mCi) | 34.2 | 36.4 | 47.5 | 37.46 | 0.597 | 0.795 | 0.918 | 0.863 |
| Dose delivered treatment 1 (Gy) | 55.6 | 54.5 | 53.7 | 54.97 | – | – | – | – |
| Prescribed activity treatment 2 (mCi) | 20.7 | – | – | – | 0.764 | 0.701 | 0.613 | 0.711 |
| Delivered activity treatment 2 (mCi) | 20.6 | – | – | – | 0.839 | 0.714 | 0.719 | 0.592 |
| Dose delivered treatment 2 (Gy) | 56.9 | – | – | – | – | – | – | – |
OS, overall survival; PFS, progression free survival.